Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

JJ Zwaginga, B. van der Holt, P.A. te Boekhorst, B.J. Biemond, M.D. Levin, R. van der Griend, A. Brand, S. Zweegman, H.F.M. Pruijt, V.M.J. Novotny, A. Vreugdenhil, M.R. de Groot, O. de Weerdt, E.C.M. van Pampus, T.M. van Maanen-Lamme, S. Wittebol, M.R. Schipperus, M.H. Silbermann, P.C. Huijgens, M. LutenR. Hollestein, J.A.C. Brakenhoff, J.G. Schrama, F.A.A. Valster, G.A. Velders, H.R. Koene

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)E90-E92
JournalHaematologica
Volume100
Issue number3
DOIs
Publication statusPublished - 2015

Cite this

Zwaginga, JJ., van der Holt, B., te Boekhorst, P. A., Biemond, B. J., Levin, M. D., van der Griend, R., ... Koene, H. R. (2015). Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients. Haematologica, 100(3), E90-E92. https://doi.org/10.3324/haematol.2014.110213